PL2877156T3 - Kompleksy chondroitynowe do wchłaniania przezskórnego - Google Patents

Kompleksy chondroitynowe do wchłaniania przezskórnego

Info

Publication number
PL2877156T3
PL2877156T3 PL13747807T PL13747807T PL2877156T3 PL 2877156 T3 PL2877156 T3 PL 2877156T3 PL 13747807 T PL13747807 T PL 13747807T PL 13747807 T PL13747807 T PL 13747807T PL 2877156 T3 PL2877156 T3 PL 2877156T3
Authority
PL
Poland
Prior art keywords
transcutaneous absorption
chondroitin
complexes
chondroitin complexes
transcutaneous
Prior art date
Application number
PL13747807T
Other languages
English (en)
Inventor
Mario De Rosa
Chiara Schiraldi
Original Assignee
Altergon S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altergon S.A. filed Critical Altergon S.A.
Publication of PL2877156T3 publication Critical patent/PL2877156T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54Polymers characterized by specific structures/properties

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13747807T 2012-07-27 2013-07-25 Kompleksy chondroitynowe do wchłaniania przezskórnego PL2877156T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001316A ITMI20121316A1 (it) 2012-07-27 2012-07-27 Complessi di condroitina ad assorbimento transcutaneo
PCT/EP2013/065733 WO2014016380A1 (en) 2012-07-27 2013-07-25 Chondroitin complexes for transcutaneous absorption
EP13747807.9A EP2877156B1 (en) 2012-07-27 2013-07-25 Chondroitin complexes for transcutaneous absorption

Publications (1)

Publication Number Publication Date
PL2877156T3 true PL2877156T3 (pl) 2020-07-27

Family

ID=46939794

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13747807T PL2877156T3 (pl) 2012-07-27 2013-07-25 Kompleksy chondroitynowe do wchłaniania przezskórnego

Country Status (13)

Country Link
US (2) US20150174258A1 (pl)
EP (1) EP2877156B1 (pl)
CN (1) CN104684542A (pl)
CA (1) CA2880012C (pl)
CY (1) CY1122538T1 (pl)
DK (1) DK2877156T3 (pl)
ES (1) ES2765199T3 (pl)
HK (1) HK1209334A1 (pl)
HU (1) HUE048502T2 (pl)
IT (1) ITMI20121316A1 (pl)
PL (1) PL2877156T3 (pl)
RU (1) RU2642612C2 (pl)
WO (1) WO2014016380A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6011734B2 (ja) * 2014-01-07 2016-10-19 株式会社村田製作所 構造材接合方法および接合構造
CN108904449A (zh) * 2018-08-20 2018-11-30 广州云雾雾化应用技术研究院(普通合伙) 一种雾态软骨素在制备修复角膜的药物中的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983000150A1 (en) * 1981-07-02 1983-01-20 Walton, Alan, G. Glycosaminoglycan drug complexes
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5639738A (en) 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5792753A (en) 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
AU730495B2 (en) * 1995-11-13 2001-03-08 North West University Administration media for analgesic, antiinflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
IT1289613B1 (it) 1997-02-07 1998-10-15 Inalco Spa Polisaccaridi batterici o-solfatati
US6987023B2 (en) 1998-04-02 2006-01-17 The Board Of Regents Of The University Of Oklahoma DNA encoding hyaluronan synthase from Pasteurella multocida and methods of use
US20030104601A1 (en) 1999-04-01 2003-06-05 Deangelis Paul L. Chondroitin synthase gene and methods of making and using same
CN101275143A (zh) 1998-04-02 2008-10-01 俄克拉何马大学董事会 编码透明质酸合酶的核酸及其应用方法
US6051587A (en) * 1998-04-16 2000-04-18 Medicure, Inc. Treatment of iatrogenic and age-related hypertension and pharmaceutical compositions useful therein
US6482401B1 (en) * 1998-12-23 2002-11-19 Naturopathic Laboratories International, Inc. Composition for the relief of joint pain and myofascial pain and method of preparing same
ITMI991465A1 (it) 1999-07-02 2001-01-02 Inalco Spa Processo per la preparazione dei polisaccaridi k4 e k5 da escherichiacoli
DE60139993D1 (de) 2000-04-25 2009-11-05 Univ Oklahoma Chondroitin synthasegen und verfahren zur dessen herstellung und anwendung
EP1270015A3 (en) * 2001-06-29 2004-02-25 Sankyo Company Limited A complex comprising OCIF and Polysaccharide
JP4702819B2 (ja) 2001-08-01 2011-06-15 生化学工業株式会社 コンドロイチン合成酵素
JP4101548B2 (ja) 2001-08-10 2008-06-18 生化学工業株式会社 コンドロイチン合成酵素及びそれをコードするdna
ITMI20012200A1 (it) 2001-10-22 2003-04-22 Ibsa Inst Biochimique Sa Processo per la preparazione di condroitin solfati dal polisaccaride k4 e prodotti ottenuti
JP4171791B2 (ja) 2002-04-30 2008-10-29 独立行政法人産業技術総合研究所 糖転移作用剤
DE60319529T2 (de) 2002-05-31 2008-10-23 Seikagaku Corp. Chondroitinsynthetase und das enzym codierende nukleinsäure
AU2003241687A1 (en) 2002-05-31 2003-12-19 Amersham Biosciences K.K. Chondroitin synthetase and dna coding for the enzyme
FR2867981B1 (fr) * 2004-03-24 2008-10-31 Genevrier Sa Lab Utilisation des chondroitine mono-et disulfates en therapeutique
US7442682B2 (en) * 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
JP4932722B2 (ja) 2005-08-24 2012-05-16 生化学工業株式会社 新規コンドロイチン画分製造方法
WO2007058252A1 (ja) 2005-11-17 2007-05-24 Seikagaku Corporation コンドロイチンの製造方法
EP1964924B1 (en) 2005-12-15 2015-09-30 Seikagaku Corporation Long-chain chondroitin sugar chain and method for producing the same and method for promoting synthesis of chondroitin
CN101466833B (zh) 2006-06-12 2011-10-19 生化学工业株式会社 经修饰的软骨素合酶多肽及其晶体
EP2106798A1 (en) * 2008-04-02 2009-10-07 Nestec S.A. Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair
JP2010173990A (ja) * 2009-01-30 2010-08-12 Alpha-Nano-Medica Co Ltd 遺伝子治療剤
IT1394311B1 (it) 2009-05-25 2012-06-06 Altergon Sa Produzione biotecnologica di condroitina
ES2661593T3 (es) * 2010-03-01 2018-04-02 Seikagaku Corporation Composiciones y métodos para producción bacteriana de condroitina
US20120094951A1 (en) * 2010-10-15 2012-04-19 Mark Robinson Compositions

Also Published As

Publication number Publication date
ES2765199T3 (es) 2020-06-08
RU2642612C2 (ru) 2018-01-25
US20150174258A1 (en) 2015-06-25
ITMI20121316A1 (it) 2014-01-28
US20190000803A1 (en) 2019-01-03
CN104684542A (zh) 2015-06-03
DK2877156T3 (da) 2020-03-02
HK1209334A1 (en) 2016-04-01
HUE048502T2 (hu) 2020-07-28
RU2015102000A (ru) 2016-09-20
EP2877156A1 (en) 2015-06-03
EP2877156B1 (en) 2020-01-01
WO2014016380A1 (en) 2014-01-30
CA2880012A1 (en) 2014-01-30
CY1122538T1 (el) 2021-01-27
US10675270B2 (en) 2020-06-09
CA2880012C (en) 2021-05-04

Similar Documents

Publication Publication Date Title
HUS2200040I1 (hu) Benzimidazol-prolin származékok
HK1213444A1 (zh) 癌症的治療
HK1207307A1 (en) Radio-pharmaceutical complexes
HK1211475A1 (en) Combination therapy
HK1203948A1 (en) Triazolopyrazine derivatives
EP2902677A4 (en) SLIDING PART
EP2931290A4 (en) PORPHYRINE-MODIFIED TELODENDRIMERS
HK1205740A1 (en) Pyrrolotriazinone derivatives
ZA201502175B (en) Oxazolidin-2-one-pyrimidine derivatives
GB201217439D0 (en) Combination therapy
GB201207305D0 (en) Therapy
HK1210426A1 (en) Combination therapy
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
HK1209334A1 (en) Chondroitin complexes for transcutaneous absorption
EP2833099A4 (en) COORDINATE CONVERTERS
IL239231A0 (en) Combined cancer treatment
GB201210358D0 (en) Complexes
IL223910A0 (en) Absorption system
ZA201303151B (en) Portal cover
GB201211543D0 (en) Combination therapy
GB201207119D0 (en) Hamason hinges